APSD of Nasal Products

Nasal drug products typically produce droplets larger than 10-20 microns, to ensure nasal deposition and minimise deposition within the lungs. However, a proportion of fine droplets in the <10 micron range may also be produced. Deposition of this respirable fraction beyond the nasal tract may be undesirable and must be quantified. Aerodynamic particle sizing with a cascade impactor is a US FDA requirement and is recommended in USP <601> to assess potential deposition beyond the nasal cavity.

Our nasal product testing solutions enable better, more informative testing in line with evolving market requirements.

Nasal Sprays
Nasal Aerosols
Nasal Powders
Nasal Sprays
Nasal Aerosols
Nasal Powders

Please select an option:

Next Generation Impactor (NGI) Andersen Cascade Impactor (ACI) Glass Twin Impinger (GTI)
Learn More

Please select an option:

Next Generation Impactor (NGI) Andersen Cascade Impactor (ACI) Glass Twin Impinger (GTI)
Learn More

Please select an option:

Next Generation Impactor (NGI) Andersen Cascade Impactor (ACI) Glass Twin Impinger (GTI)
Learn More

Related Services

Training

Training

We offer a range of training courses, presentations and seminars covering a wide range of topics.

Find Out More
Training

Servicing

A comprehensive range of both in-house and on-site product servicing options are available

Find Out More
Training

Support

Our team of experienced technicians and engineers are on hand to help and advise

Find Out More

Related News & Resources

New IPAC-RS paper offers insight and guidance for testing aqueous nasal inhalation products

2nd November 2023

Find out more

Copley introduces the new Flow Rate Sensor, a dedicated device for inhaler testing systems.

27th June 2023

Find out more

Introducing the Copley Impactor Genie™ IG 200i, a two-in-one solution for quicker, more efficient inhaled product testing

25th April 2023

Find out more

Copley launches EnviroMate™, an efficient, benchtop environmental chamber for inhaler testing

14th September 2022

Find out more

New accessory completes Copley’s solution for automated nasal drug product testing

26th October 2021

Find out more

Copley Scientific joins the Industries Forum of the Taskforce for Lung Health

22nd June 2021

Find out more

Introducing Inhalytix®: a new solution for analysing and managing inhaler test data from Copley

18th March 2021

Find out more

Copley introduces a comprehensive range for nasal product testing

11th March 2021

Find out more

Nasal Product Testing Brochure 2023 (2 mb)

View download

Perfect Timing for the Automation of OINDP Testing

View download

Nasal Drug Product Development

View download

Reducing Inhaler Testing Variability Through Test Environment Control

View download

In Vitro Regional Deposition of Nasal Sprays in an Idealized Nasal Inlet: Comparison with In Vivo Gamma Scintigraphy

View download

Refining Test Methods for a New Generation of Nasal Drug Products

View download

Semi-Automating Inhaler Testing – A Good Idea, but Where to Start?

View download

A short Q&A with our CEO, Mark Copley, On Inhaled Product Testing

View download